Cargando…

TP53 Mutations Promote Immunogenic Activity in Breast Cancer

BACKGROUND: Although immunotherapy has recently achieved clinical successes in a variety of cancers, thus far there is no immunotherapeutic strategy for breast cancer (BC). Thus, it is important to discover biomarkers for identifying BC patients responsive to immunotherapy. TP53 mutations were often...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Zhixian, Jiang, Zehang, Gao, Yingsheng, Wang, Lirui, Chen, Cai, Wang, Xiaosheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582869/ https://www.ncbi.nlm.nih.gov/pubmed/31275382 http://dx.doi.org/10.1155/2019/5952836

Ejemplares similares

Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer()
por: Jiang, Zehang, et al.
Publicado: (2018)

Correlate the TP53 Mutation and the HRAS Mutation with Immune Signatures in Head and Neck Squamous Cell Cancer
por: Lyu, Haoyu, et al.
Publicado: (2019)

TP53 mutations, expression and interaction networks in human cancers
por: Wang, Xiaosheng, et al.
Publicado: (2016)

A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
por: Liu, Zhixian, et al.
Publicado: (2018)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment
por: Jiang, Zehang, et al.
Publicado: (2019)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer
por: Li, Lin, et al.
Publicado: (2019)

Classification of gastric cancers based on immunogenomic profiling
por: Liu, Zhixian, et al.
Publicado: (2020)

Germline TP53 mutations in Finnish breast cancer patients
por: Rapakko, K, et al.
Publicado: (2000)

Clinical implications of germline mutations in breast cancer: TP53
por: Schon, Katherine, et al.
Publicado: (2017)

Impact of TP53 mutations in Triple Negative Breast Cancer
por: Mitri, Zahi I., et al.
Publicado: (2022)

Classification of triple-negative breast cancers based on Immunogenomic profiling
por: He, Yin, et al.
Publicado: (2018)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

The R337H mutation in TP53 and breast cancer in Brazil
por: Gomes, Magda CB, et al.
Publicado: (2012)

Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients
por: Alsner, J, et al.
Publicado: (2000)

Germline TP53 mutational spectrum in French Canadians with breast cancer
por: Arcand, Suzanna L, et al.
Publicado: (2015)

Expression of wild-type and mutated TP53 in breast carcinomas
por: Baumbusch, LO, et al.
Publicado: (2005)

p53 Dysregulation in Breast Cancer: Insights on Mutations in the TP53 Network and p53 Isoform Expression
por: Steffens Reinhardt, Luiza, et al.
Publicado: (2023)

Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers
por: Seagle, Brandon-Luke L., et al.
Publicado: (2015)

TP53 mutation hits energy metabolism and increases glycolysis in breast cancer
por: Harami-Papp, Hajnalka, et al.
Publicado: (2016)

Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients
por: Kwong, Ava, et al.
Publicado: (2020)

TP53 Mutations in Nonsmall Cell Lung Cancer
por: Mogi, Akira, et al.
Publicado: (2011)

The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
por: Brachova, Pavla, et al.
Publicado: (2013)

Immunohistochemical correlates of TP53 somatic mutations in cancer
por: Murnyák, Balázs, et al.
Publicado: (2016)

TP53 mutations in Romanian patients with colorectal cancer
por: Manirakiza, Felix, et al.
Publicado: (2023)

Immunometabolism characteristics and a potential prognostic risk model associated with TP53 mutations in breast cancer
por: Jiang, Mengping, et al.
Publicado: (2022)

TP53 Mutation Infers a Poor Prognosis and Is Correlated to Immunocytes Infiltration in Breast Cancer
por: Zhang, Ziwen, et al.
Publicado: (2021)

The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC
por: Wang, Shuhang, et al.
Publicado: (2020)

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
por: Eisenmann, Eric D., et al.
Publicado: (2022)

High frequency of complex TP53 mutations in CNS metastases from breast cancer
por: Lo Nigro, C, et al.
Publicado: (2012)

TP53 Mutation, Epithelial-Mesenchymal Transition, and Stemlike Features in Breast Cancer Subtypes
por: Coradini, Danila, et al.
Publicado: (2012)

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
por: Grote, Isabel, et al.
Publicado: (2021)

Somatic Mutations of TP53 and Prognostic Factors for Primary Operable Breast Cancer: Correspondence
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

TP53 somatic mutations in Asian breast cancer are associated with subtype-specific effects
por: Ragu, Mohana Eswari, et al.
Publicado: (2023)

Multimodality MRI radiomics analysis of TP53 mutations in triple negative breast cancer
por: Sun, Kun, et al.
Publicado: (2023)

Mutational processes shape the landscape of TP53 mutations in human cancer
por: Giacomelli, Andrew O., et al.
Publicado: (2018)

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms
por: Sperling, Adam S., et al.
Publicado: (2022)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_atef6ocv5npp6i6nu7007o6eea